Abstract submissions are now open for Small is Beautiful {4ever}, the 4th International Congress on Single Case Designs, taking place in Groningen, The Netherlands, from 21 to 23 April 2027. The congress brings together researchers, clinicians, educators and students from around the world to share the latest developments in single-case experimental and observational designs, personalised research methods and individualised care. Whether you are new to the field or an experien

The International Collaborative Network for N-of-1 Trials and Single-Case Designs (ICN) has submitted a public comment in response to the U.S. Food and Drug Administration’s (FDA) draft guidance, Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause. The draft guidance represents an important step towards recognising that flexible evidentiary approaches are needed

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on its proposed Rare Disease Therapies Regulatory Framework. The draft framework aims to introduce a more flexible regulatory pathway for rare disease therapies, recognising that conventional approaches to evidence generation are often not feasible for very small patient populations. These proposals are highly relevant to N-of-1 trials and single-case designs, which have the p

In January 2026, the International Collaborative Network for N-of-1 Trials and Single-Case Designs (ICN) has now grown to more than 800 members across 48 countries, reflecting the increasing global interest in personalised research and healthcare. Since its establishment, the Network has brought together researchers, clinicians and consumers committed to advancing the science and application of N-of-1 trials and single-case designs. Our members represent a broad range of disc

In July 2025, ICN welcomed Associate Professor Harriëtte Riese to its Executive Committee, further strengthening the network’s international expertise in personalised longitudinal research and single-case methodologies.